Advertisement

Behandlung der vaginalen Atrophie mit einer Kombination von Östriol und Laktobazillen

Ein klinischer Überblick
  • A. O. MueckEmail author
  • X. Ruan
  • V. Prasauskas
  • P. Grob
  • O. Ortmann
Frauengesundheit in der Praxis
  • 33 Downloads

Zusammenfassung

In den letzten Jahren wurde eine große Zahl von Studien zur Pathophysiologie der symptomatischen vulvovaginalen Atrophie (VVA) bzw. des urogenitalen Menopausesyndroms („genitourinary syndrome of menopause“ [GSM]) bei peri- und postmenopausalen Frauen und zu den Behandlungsmöglichkeiten für diese Zustände publiziert. Die Leitlinien verschiedener Gesellschaften wurden im Bereich der vaginalen Therapie von VVA/GSM aktualisiert. In diesen wird die vaginale Gabe von Östrogenen favorisiert. Die Kombination einer ultraniedrigen vaginalen Dosis von 0,03 mg Östriol (E3) und lyophilisiertem, lebensfähigem Lactobacillus acidophilus KS400 (0,03 mg E3/L) entspricht einem Produkt mit dualem Wirkmechanismus, der nicht nur die Proliferation und Reifung des Vaginalepithels, sondern auch die Wiederherstellung der laktobazillären Mikroflora fördert. Es ist hinreichend belegt, dass die Kombination ein gesundes vaginales Ökosystem schafft und aufrechterhält.

Die Anwendung verbessert die klinischen Anzeichen und Symptome sowie die Lebensqualität menopausaler Frauen, die an vaginaler Atrophie leiden, erheblich. Die Kombinationstherapie ist gut verträglich, mit einer niedrigen Gesamthäufigkeit von Nebenwirkungen und einer vernachlässigbaren systemischen Östriolresorption. Basierend auf jüngsten wissenschaftlichen Erkenntnissen und den aktuellen Behandlungsleitlinien kann die 0,03 mg-E3/L-Kombination als eine Behandlungsoption für die symptomatische vaginale Atrophie bei peri- und postmenopausalen Frauen in Betracht gezogen werden.

Schlüsselwörter

Vaginale Atrophie Urogenitales Menopausesyndrom Vaginales Östriol Vaginale Laktobazillen 

Treatment of vaginal atrophy with estriol and lactobacilli combination

A clinical review—German version

Abstract

In recent years, a vast quantity of clinical data has been accumulated on the pathophysiology of symptomatic vulvovaginal atrophy (VVA)/genitourinary syndrome of menopause (GSM) in peri- and postmenopausal women and on the treatment options for these conditions. Guidelines from several societies have recently been updated in favor of VVA/GSM vaginal therapy with the lowest possible doses of estrogens. The combination of a vaginal ultra-low dose of 0.03 mg of estriol (E3) and lyophilized, viable Lactobacillus acidophilus KS400 (0.03 mg-E3/L) is a unique product with a dual mechanism of action supporting not only the proliferation and maturation of the vaginal epithelium, but also restoration of the lactobacillary microflora. It has been demonstrated efficiently to establish and maintain a healthy vaginal ecosystem. Use of this combination considerably improves the clinical signs and symptoms as well as the quality of life of menopausal women suffering from vaginal atrophy. This combination therapy is well tolerated with a low overall incidence of side-effects and negligible estriol absorption. Based on recent scientific evidence and current treatment guidelines, the 0.03 mg-E3/L combination could be considered one of the options for the treatment of symptomatic vaginal atrophy in aging menopausal women.

Keywords

Vaginal atrophy Genitourinary syndrome of menopause Vaginal estriol Vaginal lactobacilli 

Notes

Danksagung

Die Autoren möchten sich bei Gabriela Zwyssig, Medinova AG, Schweiz, und Dr. Christian Rosé, Pierre Fabre, Deutschland, für ihre Anmerkungen zum Manuskript bedanken. Ebenfalls bedanken sie sich bei Stephan Biber, Medinova AG, Schweiz, für die wissenschaftliche Überarbeitung der deutschen Übersetzung des Manuskripts.

Förderung

Die Erstellung des Originalartikels in Climacteric und der offene Online-Zugang zur Publikation wurden von Medinova AG, Schweiz, finanziert.

Einhaltung ethischer Richtlinien

Interessenkonflikt

V. Prasauskas und P. Grob sind Mitarbeiter von Medinova AG, Schweiz. A.O. Mueck, X. Ruan und O. Ortmann hatten in den vergangenen zwei Jahren keinen Interessenkonflikt im Zusammenhang mit dieser Publikation, d. h. keine Vorträge oder Teilnahme an „advisory boards“, keine Honorare im Zusammenhang mit Produkten, die in dieser Publikation diskutiert werden. Die Verantwortung für Inhalt und Erstellung des Artikels tragen allein die Autoren.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Sturdee DW, Panay N (2010) Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 13:509–522CrossRefGoogle Scholar
  2. 2.
    Portman DJ, Gass ML (2014) Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the international society for the study of women’s sexual health and the North American menopause society. Climacteric 17:557–563CrossRefGoogle Scholar
  3. 3.
    Panay N (2015) Genitourinary syndrome of the menopause—dawn of a new era? Climacteric 18(Suppl 1):13–17CrossRefGoogle Scholar
  4. 4.
    Muhleisen AL, Herbst-Kralovetz MM (2016) Menopause and the vaginal microbiome. Maturitas 91:42–50CrossRefGoogle Scholar
  5. 5.
    Lamont R, Sobel J, Akins R et al (2011) The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG 118:533–549CrossRefGoogle Scholar
  6. 6.
    Gajer P, Brotman RM, Bai G et al (2012) Temporal dynamics of the human vaginal microbiota. Sci Transl Med 4:132ra52CrossRefGoogle Scholar
  7. 7.
    Witkin SS, Linhares IM, Giraldo P et al (2007) An altered immunity hypothesis for the development of symptomatic bacterial vaginosis. Clin Infect Dis 44:554–557CrossRefGoogle Scholar
  8. 8.
    Wilson JD, Lee RA, Balen AH et al (2007) Bacterial vaginal flora in relation to changing oestrogen levels. Int J Std Aids 18:308–311CrossRefGoogle Scholar
  9. 9.
    Wierman ME (2007) Sex steroid effects at target tissues: mechanisms of action. Adv Physiol Educ 31:26–33CrossRefGoogle Scholar
  10. 10.
    MacBride MB, Rhodes DJ, Shuster LT (2010) Vulvovaginal atrophy. Mayo Clin Proc 85:87–94CrossRefGoogle Scholar
  11. 11.
    McGroarty JA (1993) Probiotic use of lactobacilli in the human female urogenital tract. Fems Immunol Med Microbiol 6:251–264CrossRefGoogle Scholar
  12. 12.
    Redondo-Lopez V, Cook RL, Sobel JD (1990) Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev Infect Dis 12:856–872CrossRefGoogle Scholar
  13. 13.
    Archer DF (2010) Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 17:194–203CrossRefGoogle Scholar
  14. 14.
    Bachmann GA, Nevadunsky NS (2000) Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 61:3090–3096PubMedGoogle Scholar
  15. 15.
    Ruan X, Mueck AO (2015) Impact of smoking on estrogenic efficacy. Climacteric 18:38–46CrossRefGoogle Scholar
  16. 16.
    Kanne B, Jenny J (1991) Local administration of low-dosed estriol and viable Lactobacillus acidophilus in the post-menopausal period. Gynäkol Rundsch 31:7–13 (German)CrossRefGoogle Scholar
  17. 17.
    Nappi RE, Palacios S (2014) Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 17:3–9CrossRefGoogle Scholar
  18. 18.
    Krychman M, Graham S, Bernick B et al (2017) The Women’s EMPOWER survey: women’s knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate. J Sex Med 14:425–433CrossRefGoogle Scholar
  19. 19.
    Weber MA, Limpens J, Roovers JP (2015) Assessment of vaginal atrophy: a review. Int Urogynecol J 26:15–28CrossRefGoogle Scholar
  20. 20.
    Simon JA (2011) Identifying and treating sexual dysfunction in postmenopausal women: the role of estrogen. J Womens Health (larchmt) 20:1453–1465CrossRefGoogle Scholar
  21. 21.
    Nappi RE, Kokot-Kierepa M (2010) Women’s voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 67:233–238CrossRefGoogle Scholar
  22. 22.
    Weber MA, Kleijn MH, Langendam M et al (2015) Local oestrogen for pelvic floor disorders: a systematic review. PLoS ONE 10:e136265CrossRefGoogle Scholar
  23. 23.
    Baber RJ, Panay N, Fenton A et al (2016) 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric 19:109–150CrossRefGoogle Scholar
  24. 24.
    de Villiers TJ, Gass ML, Haines CJ et al (2013) Global consensus statement on menopausal hormone therapy. Climacteric 16:203–204CrossRefGoogle Scholar
  25. 25.
    North American Menopause Society (NAMS) (2013) Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 20:888–902CrossRefGoogle Scholar
  26. 26.
    Lumsden MA, Davies M, Sarri G et al (2016) Diagnosis and management of menopause: the National Institute of Health and Care Excellence (NICE) guideline. Jama Intern Med 176:1205–1206CrossRefGoogle Scholar
  27. 27.
    Neves-e-Castro M, Birkhauser M, Samsioe G et al (2015) EMAS position statement: the ten point guide to the integral management of menopausal health. Maturitas 81:88–92CrossRefGoogle Scholar
  28. 28.
    Ortmann O, Lattrich C (2012) The treatment of climacteric symptoms. Dtsch Arztebl Int 109:316–323PubMedPubMedCentralGoogle Scholar
  29. 29.
    Ortmann O, Doren M, Windler E et al (2011) Hormone therapy in perimenopause and postmenopause (HT). Interdisciplinary S3 guideline, association of the scientific medical societies in Germany AWMF 015/062-short version. Arch Gynecol Obstet 284:343–355CrossRefGoogle Scholar
  30. 30.
    Nikander E, Kilkkinen A, Metsa-Heikkila M et al (2003) A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet Gynecol 101:1213–1220PubMedGoogle Scholar
  31. 31.
    Bruyniks N, Biglia N, Palacios S et al (2017) Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy. Climacteric 20:195–204CrossRefGoogle Scholar
  32. 32.
    Iosif CS (1992) Effects of protracted administration of estriol on the lower genito urinary tract in postmenopausal women. Arch Gynecol Obstet 251:115–120CrossRefGoogle Scholar
  33. 33.
    Palacios S (2008) Advances in hormone replacement therapy: making the menopause manageable. BMC Womens Health 8:22CrossRefGoogle Scholar
  34. 34.
    Suckling JA, Kennedy R, Lethaby A et al (2006) Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.cd001500.pub2 CrossRefPubMedGoogle Scholar
  35. 35.
    Head KA (1998) Estriol: safety and efficacy. Altern Med Rev 3:101–113PubMedGoogle Scholar
  36. 36.
    Englund DE, Elamsson KB, Johansson EDB (1982) Bioavailability of oestriol. Acta Endocrinol 99:136–140CrossRefGoogle Scholar
  37. 37.
    Keller PJ, Riedmann R, Fischer M (1980) Oestrone, oestradiol and oestriol content following intravaginal application of oestriol in the postmenopause. Gynäkol Rundsch 20:77–79 (German)CrossRefGoogle Scholar
  38. 38.
    Trinkaus M, Chin S, Wolfman W et al (2008) Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist 13:222–231CrossRefGoogle Scholar
  39. 39.
    Palacios S, Castelo-Branco C, Cancelo MJ et al (2005) Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy. Maturitas 50:98–104CrossRefGoogle Scholar
  40. 40.
    Heimer GM, Englund DE (1986) Plasma oestriol following vaginal administration: morning versus evening insertion and influence of food. Maturitas 8:239–243CrossRefGoogle Scholar
  41. 41.
    van der Vies J (1982) The pharmacology of oestriol. Maturitas 4:291–299CrossRefGoogle Scholar
  42. 42.
    Bergink EW (1980) Oestriol receptor interactions: their biological importance and therapeutic implications. Acta Endocrinol 233:9–16Google Scholar
  43. 43.
    Lokuge S, Frey BN, Foster JA et al (2010) The rapid effects of estrogen: a mini-review. Behav Pharmacol 21:465–472CrossRefGoogle Scholar
  44. 44.
    Longcope C (1984) Estriol production and metabolism in normal women. J Steroid Biochem 20:959–962CrossRefGoogle Scholar
  45. 45.
    Fink RS, Collins WP, Papadaki L et al (1985) Vaginal oestriol: effective menopausal therapy not associated with endometrial hyperplasia. J Gynaecol Endocrinol I:1–11Google Scholar
  46. 46.
    Genazzani AR, Inaudi P, la Rosa R et al (1982) Oestriol and the menopause: clinical and endocrinological results of vaginal administration. In: Fioretti P, Martini L, Melis GB et al (Hrsg) The menopause: clinical, endocrinological and pathophysiological aspects. Serono Symposium No. 39. Academic Press, London, S 539–550Google Scholar
  47. 47.
    Mattsson L‑A, Cullberg G (1983) Vaginal absorption of two estriol preparations: a comparative study in post-menopausal women. Acta Obstet Gynecol Scand 62:393–396CrossRefGoogle Scholar
  48. 48.
    Rauramo L, Punnonen R, Grönroos M (1978) Serum oestrone, oestradiol and oestriol concentrations during oral oestradiol valerate and oestriol succinate therapy in ovariectomized women. Maturitas 1:79–85CrossRefGoogle Scholar
  49. 49.
    van Haaften M, Donker GH, Haspels AA et al (1989) Oestrogen concentrations in plasma, endometrium, myometrium and vagina of postmenopausal women, and effects of vaginal oestriol (E3) and oestradiol (E2) applications. J Steroid Biochem 33:647–653CrossRefGoogle Scholar
  50. 50.
    Bundesgesundheitsamt (BGA), Kommission B4 (1993) B. Processing Monograph Estriol. Daz 133:858 (German)Google Scholar
  51. 51.
    Furuhjelm M, Karlgren E, Carlström K (1980) Intravaginal administration of conjugated estrogens in premenopausal and postmenopausal women. Int J Gynaecol Obstet 17:335–339CrossRefGoogle Scholar
  52. 52.
    Samsioe G (1998) Urogenital aging—a hidden problem. Am J Obstet Gynecol 178:S245–9CrossRefGoogle Scholar
  53. 53.
    Donders G, Neven P, Moegele M et al (2014) Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat 145:371–379CrossRefGoogle Scholar
  54. 54.
    Ponzone R, Biglia N, Jacomuzzi ME et al (2005) Vaginal oestrogen therapy after breast cancer: is it safe? Eur J Cancer 41:2673–2681CrossRefGoogle Scholar
  55. 55.
    van Haaften M, Donker GH, Sie-Go DM et al (1997) Biochemical and histological effects of vaginal estriol and estradiol applications on the endometrium, myometrium and vagina of postmenopausal women. Gynecol Endocrinol 11:175–185CrossRefGoogle Scholar
  56. 56.
    Vooijs GP, Geurts TBP (1995) Review of the endometrial safety during intravaginal treatment with estriol. Eur J Obstet Gynecol 62:101–106CrossRefGoogle Scholar
  57. 57.
    Buhling KJ, Eydeler U, Borregaard S et al (2012) Systemic bioavailability of estriol following single and repeated vaginal administration of 0.03 mg estriol containing pessaries. Arzneimittelforschung 62:378–383CrossRefGoogle Scholar
  58. 58.
    Cano A, Estevez J, Usandizaga R et al (2012) The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005 % estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a Pivotal Phase III Study. Menopause 19:1130–1139CrossRefGoogle Scholar
  59. 59.
    Capobianco G, Wenger JM, Meloni GB et al (2014) Triple therapy with Lactobacilli acidophili, estriol plus pelvic floor rehabilitation for symptoms of urogenital aging in postmenopausal women. Arch Gynecol Obstet 289:601–608CrossRefGoogle Scholar
  60. 60.
    Griesser H, Skonietzki S, Fischer T et al (2012) Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2 mg and 0.03 mg estriol. Maturitas 71:360–368CrossRefGoogle Scholar
  61. 61.
    Jaisamrarn U, Triratanachat S, Chaikittisilpa S et al (2013) Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy: a double-blind randomized trial followed by open-label maintenance therapy. Climacteric 16:347–355CrossRefGoogle Scholar
  62. 62.
    Caruso S, Cianci S, Amore FF et al (2016) Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel. Menopause 23:47–54CrossRefGoogle Scholar
  63. 63.
    Barbes C, Boris S (1999) Potential role of lactobacilli as prophylactic agents against genital pathogens. Aids Patient Care Stds 13:747–751CrossRefGoogle Scholar
  64. 64.
    Schöni M, Graf F, Meier B (1988) Treatment of vaginal disorders with Döderlein bacteria. Saz 126:139–142 (German)Google Scholar
  65. 65.
    Vaneechoutte M (2017) The human vaginal microbial community. Res Microbiol 168:811–825CrossRefGoogle Scholar
  66. 66.
    Unlu C, Donders G (2011) Use of lactobacilli and estriol combination in the treatment of disturbed vaginal ecosystem: a review. J Turk Ger Gynecol Assoc 12:239–246CrossRefGoogle Scholar
  67. 67.
    Anahtar MN, Byrne EH, Doherty KE et al (2015) Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity 42:965–976CrossRefGoogle Scholar
  68. 68.
    Witkin SS, Linhares IM, Giraldo P (2007) Bacterial flora of the female genital tract: function and immune regulation. Best Pract Res Clin Obstet Gynaecol 21:347–354CrossRefGoogle Scholar
  69. 69.
    Hummelen R, Macklaim JM, Bisanz JE et al (2011) Vaginal microbiome and epithelial gene array in post-menopausal women with moderate to severe dryness. PLoS ONE 6:e26602CrossRefGoogle Scholar
  70. 70.
    Shen J, Song N, Williams CJ et al (2016) Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis. Sci Rep 6:24380CrossRefGoogle Scholar
  71. 71.
    Borges S, Silva J, Teixeira P (2014) The role of lactobacilli and probiotics in maintaining vaginal health. Arch Gynecol Obstet 289:479–489CrossRefGoogle Scholar
  72. 72.
    Kaiser RR, Michael-Hepp J, Weber W et al (2000) Absorption of estriol from vaginal tablets after single and repeated application in healthy, postmenopausal women. Therapiewoche 3:2–8Google Scholar
  73. 73.
    Feiks A, Grunberger W (1991) Treatment of atrophic vaginitis: does topical application allow a reduction in the oestrogen dose? Gynäkol Rundsch 31(Suppl 2):268–271 (German)CrossRefGoogle Scholar
  74. 74.
    Sousa MS, Peate M, Jarvis S et al (2017) A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy. Ther Adv Med Oncol 9:269–285CrossRefGoogle Scholar
  75. 75.
    Buchholz S, Mogele M, Lintermans A et al (2015) Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer. Climacteric 18:252–259CrossRefGoogle Scholar
  76. 76.
    Donders G, Bellen G, Neven P et al (2015) Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor(R)) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors. Eur J Clin Microbiol Infect Dis 34:2023–2028CrossRefGoogle Scholar
  77. 77.
    Kanne B, Patz B, Wackerle L (1986) Local treatment of vaginal infections with Doederlein bacteria and estriol in climacterium and senium. Frauenarzt 3:35–40 (German)Google Scholar
  78. 78.
    Barrons R, Tassone D (2008) Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review. Clin Ther 30:453–468CrossRefGoogle Scholar
  79. 79.
    Panay N, Fenton A (2014) Vulvovaginal atrophy—a tale of neglect. Climacteric 17:1–2PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  • A. O. Mueck
    • 1
    • 2
    Email author
  • X. Ruan
    • 1
    • 2
  • V. Prasauskas
    • 3
  • P. Grob
    • 3
  • O. Ortmann
    • 4
  1. 1.Bereiche Endokrinologie und Menopause, Department für FrauengesundheitUniversitätsklinikum TübingenTübingenDeutschland
  2. 2.Abteilung für gynäkologische Endokrinologie, Klinik für Gynäkologie und Geburtshilfe PekingCapital Medical UniversityPekingChina
  3. 3.Wissenschaftliche und Medizinische AbteilungMedinova AGZürichSchweiz
  4. 4.Klinik für Gynäkologie und GeburtshilfeUniversität RegensburgRegensburgDeutschland

Personalised recommendations